ClinicalTrials.gg
CompletedNCT00402350Updated Mar 15, 2017

Staccato Fentanyl Single and Multidose PK

A Phase 1 interventional study of Inhaled Placebo and Inhaled Fentanyl 25 mcg in Breakthrough Pain, sponsored by Alexza Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by Alexza Pharmaceuticals, Inc. (part of Ferrer Internacional S.A.) · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The Phase I clinical trial in approximately 50 healthy volunteers will be conducted at a single clinical center in two stages. Stage 1 is an open-label, cross-over comparison of a single dose of Staccato Fentanyl and an equivalent dose of intravenous (IV) fentanyl. Stage 2 is a randomized, doubleblind, placebo-controlled dose escalation of Staccato Fentanyl, evaluating multiple doses of fentanyl. The three primary aims of the Phase I clinical trial are to evaluate the pharmacokinetics (PK) and absolute bioavailability for Fentanyl, compare the Staccato Fentanyl PK profile to the IV fentanyl PK profile, and examine the tolerability and safety of Staccato Fentanyl in a non-opioid-tolerant, healthy volunteer population.

02

Conditions studied

  • Breakthrough Pain

Browse trials for

Keywords

  • Staccato Fentanyl, Pharmacokinetics, Pharmacodynamics, inhaled fentanyl
03

In context

Breakthrough Pain

34 studies on the registry are indexed under Breakthrough Pain; 4 are open to participants now.

This study's enrollment of 51 is below the median of 91 across 21 interventional studies indexed under Breakthrough Pain.

Browse Breakthrough Pain studies →

Lead sponsor

Alexza Pharmaceuticals, Inc. is the lead sponsor of 26 studies on the registry; none are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 14 (58%) have results posted.

First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects between the ages of 18 to 55 years, inclusive.
  2. Subjects with a (BMI) ≥ 21 and ≤ 30.
  3. Female subjects who are not pregnant, or are surgically sterile or 2 years . If of , she must be using a medically-accepted method of and agree to continue use of this method for at least 30 days after the study (i.e., barrier method with spermicide, steroidal contraceptive [oral, transdermal, and implanted, including Depo-Provera; contraceptives must be used in conjunction with a barrier method], or intrauterine device).
  4. Subjects who speak, read, and understand English and are willing and able to provide written on an IRB-approved form prior to the initiation of any study procedures.
  5. Subjects who are willing and able to be confined to the Clinical Research Unit (CRU) for approximately 10 hours and comply with the study schedule and study requirements.
  6. Subjects who are in good general health as determined by a complete medical history, physical examination, 12-lead , spirometry, blood chemistry profile, hematology, and urinalysis.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who regularly consume large amounts of xanthine-containing substances (i.e., more than 5 cups of coffee or equivalent amounts of xanthine-containing substances per day).
  2. Subjects who have taken prescription or nonprescription medication (with the exception of vitamins, acetaminophen, and steroidal for women of if medically necessary) within 5 days of Visits 2 or 3.
  3. Subjects who have had an acute illness within 5 days of either Visit 2 or 3.
  4. Subjects who have received an drug within 30 days (or within 5 half lives of the investigational drug) prior to Visit 2 or 3.
  5. Subjects who have smoked tobacco within the last year.
  6. Subjects who have a history within the past 2 years of drug or alcohol dependence or abuse as defined by DSM-4.
  7. Subjects with a history of positivity.
  8. Subjects with a history of allergy or intolerance to opioids.
  9. Subjects who test positive for alcohol or have a positive urine drug screen at any study visit.
  10. Subjects who have hypotension (systolic blood pressure ≤90 mmHg, diastolic blood pressure ≤50 mmHg), or hypertension (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg).
  11. Subjects who have a abnormality (beyond 1st degree heart block).
  12. Subjects with a history of unstable angina, syncope, coronary artery disease, myocardial infarction, congestive heart failure (CHF), stroke, (TIA), or a significant neurological disorder.
  13. Subjects who have a history of pulmonary disease (asthma, bronchitis, bronchospasm, emphysema).
  14. Subjects who have an less than 80% of predicted values on spirometry assessments at Visit 1.
  15. Female subjects who are breastfeeding or have a positive pregnancy test at any visit must be excluded.
  16. Subjects who have any other disease or condition, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects (2) from each of the 4 dose escalation arms

    Drug: Inhaled Placebo

  • Experimental
    25 mcg IV and Inhaled Crossover

    Single dose crossover (IV vs Inhaled)

    Drug: Inhaled Fentanyl 25 mcg · Drug: Intravenous Fentanyl 25 mcg

  • Experimental
    Inhaled fentanyl 25 mcg x 2

    Inhaled Staccato fentanyl, 25 mcg x 2

    Drug: Inhaled Fentanyl 25 mcg x 2

  • Experimental
    Inhaled fentanyl 25 mcg x 4

    Inhaled Staccato fentanyl, 25 mcg x 4

    Drug: Inhaled Fentanyl 25 mcg x 4

  • Experimental
    Inhaled fentanyl 25 mcg x 6

    Inhaled Staccato fentanyl, 25 mcg x 6

    Drug: Inhaled Fentanyl 25 mcg x 6

  • Experimental
    Inhaled fentanyl 25 mcg x 12

    Inhaled Staccato fentanyl, 25 mcg x 12

    Drug: Inhaled Fentanyl 25 mcg x 12

Interventions

06

What researchers measure

Primary outcomes

  1. To establish the plasma PK profile of fentanyl following single and multiple Staccato Fentanyl doses

    Time frame: 8 hours

Secondary outcomes

  1. To assess Staccato Fentanyl absolute bioavailability and dose proportionality

    Time frame: 8 hours

  2. Safety and Tolerability of Staccato Fentanyl

    Time frame: 8 hours

07

Study locations

1 site
  • Duke University
    Durham, North Carolina 27710, United States
08

References and documents

Publications

  • Macleod DB, Habib AS, Ikeda K, Spyker DA, Cassella JV, Ho KY, Gan TJ. Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. Anesth Analg. 2012 Nov;115(5):1071-7. doi: 10.1213/ANE.0b013e3182691898. Epub 2012 Sep 13. PubMed 22984155 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2006
First posted
Nov 22, 2006
Start
Apr 2006
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00402350
Responsible party
Sponsor
First posted
Nov 22, 2006
Start date
Apr 2006
Primary completion
Nov 2006
Completion
Nov 2006
Last update
Mar 15, 2017

Study contacts

Tong J Gan, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fentanyl

Start the discussion